EcoDrugPlus

C-C Chemokine Receptor Type 9-Like

Ensembl ID : ENSAOCG00000015536
Gene Symbol: LOC111568782
3 Cross references
190 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSAOCG00000003649
Gene Symbol: CCR9
3 Cross references
194 Possible Orthologues:

C-X-C Chemokine Receptor Type 4-Like

Ensembl ID : ENSAOCG00000011574
Gene Symbol: LOC111571831
3 Cross references
216 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSAOCG00000002453
Gene Symbol: CXCR1
3 Cross references
275 Possible Orthologues:

C-Reactive Protein-Like

Ensembl ID : ENSAOCG00000008978
Gene Symbol: LOC111562989
2 Cross references
356 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSAOCG00000008153
Gene Symbol: CFTR
3 Cross references
195 Possible Orthologues:

D(3) Dopamine Receptor-Like

Ensembl ID : ENSAOCG00000009664
Gene Symbol: LOC111565955
3 Cross references
203 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSAOCG00000005562
Gene Symbol: LOC111582546
3 Cross references
175 Possible Orthologues:

D(4) Dopamine Receptor-Like

Ensembl ID : ENSAOCG00000007125
Gene Symbol: LOC111575966
3 Cross references
150 Possible Orthologues:

Dna Methyltransferase 1

Ensembl ID : ENSAOCG00000005339
Gene Symbol: DNMT1
3 Cross references
212 Possible Orthologues:

Dna Topoisomerase 1-Like

Ensembl ID : ENSAOCG00000020616
Gene Symbol: LOC111573981
3 Cross references
208 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSAOCG00000019964
Gene Symbol: TOP1
1 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).